openPR Logo
Press release

CAMP and cAMP Inhibited cGMP 3’5’ Cyclic Phosphodiesterase 10A Market 2021 New Research Study

10-02-2017 03:31 PM CET | Health & Medicine

Press release from: ReportsWeb

ReportsWeb

ReportsWeb

ReportsWeb.com published “CAMP and cAMP Inhibited cGMP 3’5’ Cyclic Phosphodiesterase 10A-Pipeline Review H2 2017” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months.
Original Content:
cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report cAMP and cAMP Inhibited cGMP 3' - Pipeline Review, H1 2017, outlays comprehensive information on the cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A is an enzyme which plays a critical role in regulating cAMP and cGMP levels in the striatum. Many cellular responses are regulated by second messengers like cAMP and cGMP. PDE10A eliminate cAMP- and cGMP-mediated intracellular signaling by hydrolyzing the cyclic nucleotide to the corresponding nucleoside 5-prime monophosphate. The molecules developed by companies in Phase I and Preclinical stages are 1 and 11 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Oncology which include indications Schizophrenia, Huntington Disease, Lung Cancer, Psychiatric Disorders, Psychosis and Cognitive Disorders.
For more information about this report: http://www.reportsweb.com/camp-and-camp-inhibited-cgmp-35-cyclic-phosphodiesterase-10a-pipeline-review-h1-2017
Furthermore, this report also reviews key players involved in cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Report Scope
- The report provides a snapshot of the global therapeutic landscape for cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35)
- The report reviews cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics and enlists all their major and minor projects
- The report assesses cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001834451/sample
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of CAMP and cAMP Inhibited cGMP 3’5’ Cyclic Phosphodiesterase 10A to Infectious Disease Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of CAMP and cAMP Inhibited cGMP 3’5’ Cyclic Phosphodiesterase 10A to Infectious Disease Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in CAMP and cAMP Inhibited cGMP 3’5’ Cyclic Phosphodiesterase 10A Therapeutics Clinical Trials 26
Prominent Drugs 27
Clinical Trial Profile Snapshots 28
Inquire before Buying at http://www.reportsweb.com/buy&RW0001834451/buy/3500
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Pune:
505, 6th floor, Amanora Township,
Amanora Chambers, East Block,
Kharadi Road, Hadapsar, Pune-411028

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CAMP and cAMP Inhibited cGMP 3’5’ Cyclic Phosphodiesterase 10A Market 2021 New Research Study here

News-ID: 750444 • Views:

More Releases from ReportsWeb

North America: Smart Airport Market Overall Study Report 2020-2026| Amadeus IT Group S.A., Cisco, Honeywell, IBM, QinetiQ Group Plc, Sabre Corporation, Siemens ,Rockwell Collins Inc, Thales Group and T Systems International GmbH
North America: Smart Airport Market Overall Study Report 2020-2026| Amadeus IT G …
The "Global North America Smart Airport Market: 2020" Industry Report is a professional and in-depth study on the current state of the North America Smart Airport Market by PMR. The North America Smart Airport market is supposed to demonstrate a considerable growth during the forecast period of 2020 - 2026. The company profiles of all the key players and brands that are dominating the market have been given in this
Marine Biotechnology Market Future Forecast 2018-2026 by Leading Companies such as BASF, Abbott Laboratories, Lonza Group, Nofima, Aker Biomarine, Cyanotech Corporation, New England Biolabs, GlycoMar, Pharmamara, Nutrex Hawaii Incorporated, Marinova, Fmc
Marine Biotechnology Market Future Forecast 2018-2026 by Leading Companies such …
ReportsWeb.com has announced the addition of the “Marine Biotechnology-Global Market Outlook 2017-2026” The report classifies the global Marine Biotechnology Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. According to Publisher, the Global Marine Biotechnology Market is accounted for $3.93 billion in 2017 and is expected to reach $8.74 billion by 2026 growing at a CAGR of 9.3% during
Anti-Counterfeiting Packaging Market Growth Opportunities and Emerging Trends by Analysis of Key Vendors like Alien Technology, 3M Company, Acg Pharmapack, Advanced Track & Trace, AlpVision S.A., Angstrom Technologies, Atlantic Zeiser, TruTag Technologies
Anti-Counterfeiting Packaging Market Growth Opportunities and Emerging Trends by …
ReportsWeb.com has announced the addition of the “Anti-Counterfeiting Packaging-Global Market Outlook 2017-2026” The report classifies the global Anti-Counterfeiting Packaging Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. According to Publisher, the Global Anti-Counterfeiting Packaging Market is accounted for $112.16 billion in 2017 and is expected to reach $427.96 billion by 2026 growing at a CAGR of 16.0% during
Solar Photovoltaic in Italy Market Outlook to 2030 | Company Profiles (Tozzi Holding, Silver Ridge Power, RTR Capital, Mitsubishi Corporation, Etrion Corporation)
Solar Photovoltaic in Italy Market Outlook to 2030 | Company Profiles (Tozzi Hol …
Solar Photovoltaic (PV) in Italy, Market Outlook to 2030, Update 2018-Capacity, Generation, Investment Trends, Regulations and Company Profiles Summary "Solar Photovoltaic (PV) in Italy, Market Outlook to 2030, Update 2018-Capacity, Generation, Investment Trends, Regulations and Company Profiles", is the latest report from Publisher, the industry analysis specialists that offer comprehensive information and understanding of the Solar Photovoltaic (PV) market in Italy. The report provides in depth analysis on global renewable power market and

All 4 Releases


More Releases for Phosphodiesterase

Phosphodiesterase Enzyme (PDE) Inhibitors Market Report 2022: Includes Latest Ke …
Phosphodiesterase Enzyme (PDE) Inhibitors Market report studies the Phosphodiesterase Enzyme (PDE) Inhibitors with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Phosphodiesterase Enzyme (PDE) Inhibitors Market analysis segmented by companies, region, type and applications in the report. Scope of Phosphodiesterase Enzyme (PDE) Inhibitors:
Global Phosphodiesterase (PDE) Inhibitors Market 2021 Analysis May Set New Growt …
The global phosphodiesterase (PDE) inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The PDE is found in the cytosol, plasma membranes, endoplasmic reticulum, nuclear membranes, and cytoskeleton. Majorly, the two types of PDE inhibitors including the selective and non-selective are being discovered as possible treatments for various indications, such as chronic obstructive pulmonary disease (COPD), Alzheimer’s disease, and other ailments. Thus, such novel
Phosphodiesterase Inhibitor Industry Market 2019 Analysis & Forecast To 2025 By …
A report on ‘Phosphodiesterase Inhibitor Industry Market’ Added by Upmarketresearch.com, features the recent and upcoming growth trends of this business in addition to accurate details related to the myriad geographies that comprise the regional spectrum of the Phosphodiesterase Inhibitor Industry market. Furthermore, the report elucidates complex details about the supply-demand analysis, industry share, growth statistics and participation of major players in the Phosphodiesterase Inhibitor Industry market. Request a sample Report of
Phosphodiesterase Enzyme (PDE) Inhibitors Market - Global Industry Insights, Tre …
Phosphodiesterase are a diverse family of enzymes (11 isoenzymes) that play a key role in regulating intracellular levels of secondary messengers - cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate. These enzymes identified to be pharmacologically active in the 1950s, hydrolyses cyclic nucleotides to treat various diseases such as cardiovascular, respiratory and erectile dysfunction. Distinct distribution of all the types of isoenzymes has provided possibilities for selective target therapies. Request Sample
Phosphodiesterase Enzyme (PDE) Inhibitors Market Opportunity Analysis, 2018-2026
Phosphodiesterase are a diverse family of enzymes (11 isoenzymes) that play a key role in regulating intracellular levels of secondary messengers - cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate. These enzymes identified to be pharmacologically active in the 1950s, hydrolyses cyclic nucleotides to treat various diseases such as cardiovascular, respiratory and erectile dysfunction. Distinct distribution of all the types of isoenzymes has provided possibilities for selective target therapies. Request a
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 - Pipeline Revi …
“Ectonucleotide Pyrophosphatas Family” Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) is an enzyme encoded by the ENPP2 gene. It stimulates migration of melanoma cells. It has a role in induction of parturition. It is involved in cell proliferation and adipose tissue development. Request For Free Sample @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157728 Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D